Literature DB >> 19769555

Gaps in cardiovascular disease risk management in Australian general practice.

Ruth J Webster1, Emma L Heeley, David P Peiris, Clare Bayram, Alan Cass, Anushka A Patel.   

Abstract

OBJECTIVE: To evaluate the management of cardiovascular disease (CVD) risk in Australian general practice. DESIGN, SETTING AND PARTICIPANTS: National cross-sectional survey of 99 Australian general practitioners participating in the Bettering the Evaluation and Care of Health (BEACH) program. Data on 2618 consecutive adult patients presenting to the participating GPs over a 5-week period from September to October 2006 were analysed. MAIN OUTCOME MEASURES: Proportions of patients screened, treated and reaching targets according to (1) current Australian CVD risk guidelines and (2) overall or absolute CVD risk.
RESULTS: Blood pressure (BP) had not been recorded for 13% of the sample. Of 1400 patients not prescribed antihypertensive medication, treatment was indicated for 8%. Of 821 patients already prescribed antihypertensive medication, 59% were achieving target BPs. Data on low-density lipoprotein (LDL) cholesterol levels were not available for 53% of the 2175 patients who should have had lipid screening according to the guidelines. Of 624 patients not prescribed a statin, treatment was indicated for 41%. Of 368 already prescribed a statin, 62% were achieving target LDL cholesterol levels. Sufficient data for calculation of absolute risk had been recorded for 74% of the 1736 patients for whom such calculation was recommended by the guidelines. The remaining 26% either had at least one required variable unmeasured (20%) or missing from the data collection (6%). For those at high absolute CVD risk (without established disease) and those with established CVD, 23% and 53%, respectively, had been prescribed both antihypertensive medication and a statin.
CONCLUSIONS: Gaps between guideline recommendations and practice in recording and managing BP were relatively low compared with gaps for lipids. When stratified by absolute risk, patients at high risk of a cardiovascular event were found to be substantially undertreated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19769555

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  37 in total

1.  Does upsizing statins have a downside?

Authors:  Andrew J Brown
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

2.  The Fremantle Primary Prevention Study: a multicentre randomised trial of absolute cardiovascular risk reduction.

Authors:  Tom Brett; Diane Arnold-Reed; Cam Phan; Frances Cadden; William Walker; Wendy Manea-Walley; Noelene Mora; Julie Young; Max Bulsara
Journal:  Br J Gen Pract       Date:  2012-01       Impact factor: 5.386

Review 3.  Harnessing health IT for improved cardiovascular risk management.

Authors:  Sue Wells; Robyn Whittaker; Enid Dorey; Chris Bullen
Journal:  PLoS Med       Date:  2010-08-24       Impact factor: 11.069

4.  Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk.

Authors:  Hueiming Liu; Anushka Patel; Alex Brown; Sandra Eades; Noel Hayman; Stephen Jan; Ian Ring; Greg Stewart; Andrew Tonkin; Tarun Weeramanthri; Vicki Wade; Anthony Rodgers; Tim Usherwood; Bruce Neal; David Peiris; Hugh Burke; Christopher Reid; Alan Cass
Journal:  BMC Public Health       Date:  2010-08-05       Impact factor: 3.295

5.  Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy.

Authors:  David Colquhoun; Diana Chirovsky; Valsilisa Sazonov; Yadong A Cui; Baishali Ambegaonkar
Journal:  Exp Clin Cardiol       Date:  2013

6.  Does tablet formulation alone improve adherence and persistence: a comparison of ezetimibe fixed dose combination versus ezetimibe separate pill combination?

Authors:  Louise E Bartlett; Nicole Pratt; Elizabeth E Roughead
Journal:  Br J Clin Pharmacol       Date:  2016-09-29       Impact factor: 4.335

Review 7.  Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.

Authors:  Ruth Webster; Anthony Rodgers
Journal:  Curr Cardiol Rep       Date:  2015-12       Impact factor: 2.931

8.  Improving attendance for cardiovascular risk assessment in Australian general practice: an RCT of a monetary incentive for patients.

Authors:  Nigel Stocks; James Allan; Oliver Frank; Sue Williams; Philip Ryan
Journal:  BMC Fam Pract       Date:  2012-06-08       Impact factor: 2.497

9.  An electronic clinical decision support tool to assist primary care providers in cardiovascular disease risk management: development and mixed methods evaluation.

Authors:  David P Peiris; Rohina Joshi; Ruth J Webster; Patrick Groenestein; Tim P Usherwood; Emma Heeley; Fiona M Turnbull; Alexandra Lipman; Anushka A Patel
Journal:  J Med Internet Res       Date:  2009-12-17       Impact factor: 5.428

10.  Strategies for prevention of cardiovascular disease in adults with hypertension.

Authors:  Paul K Whelton; Norm R C Campbell; Daniel T Lackland; Gianfranco Parati; C Venkata S Ram; Michael A Weber; Xin-Hua Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-31       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.